Quick search:
Content Search
Result Content Research
Result Content Research
1 Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors
2 Novartis CEO says Covid-related doctor visit delays likely impacting cancer diagnosis rates
3 Novartis posts second-quarter profit beat, keeps 2021 guidance
4 Novartis inks 10-year pledge to co-create solutions for health equity
5 Novartis on the hook for $178M after losing Tafinlar patent fight with Daiichi's Plexxikon business
6 Novartis inks 10-year pledge to improve equity in research, care
7 Novartis set to deliver 50 million CureVac COVID-19 vaccines this year
8 Novartis Leading in $10 Billion Market for New Cancer Treatment
9 Novartis aims to beat rivals to novel $10bn cancer treatment market
10 Is Entresto maker Novartis scared of Jardiance's landmark heart failure win? Not really, exec says
11 Roche takes the Tim-3 battle to Novartis
12 Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer
13 AGC Bio buying CO plant from Novartis
14 Novartis Q2 Revenues Grow 14 Percent
15 Novartis to make Leqvio for U.S. in Austria to overcome FDA delay
16 Novartis is about to start ringing up peers to join ambitious new diversity program
17 Novartis in East Hanover approved to sell off 62 of 202 acres
18 Novartis Owes Plexxikon $178 Million in Drug Patent Fight (3)
19 Novartis ditches midstage dry eye drug, gets New Year's PDUFA data for troubled Leqvio
20 Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged
21 Novartis Delivers Strong Second Quarter and 50 Million CureVac Vaccines
22 Fierce Pharma Asia—Junshi's mRNA JV; Novartis' China business; Roche's Ronapreve COVID nod in Japan
23 AGC Biologics to buy Novartis facility in Longmont
24 Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report
25 Top Stock Reports for Apple, Danaher & Novartis
26 Novartis reshuffles its wild cards; Tough sell for Biogen? Googling proteins; Ken Frazier's new gig; and more
27 Novartis contends Roche 'unjustly enriched' itself with $210 mln in fees -lawsuit
28 Novartis, Kura Oncology Partner on Phase I/II Head and Neck Cancer Study of Piqray, Tipifarnib
29 Novartis Looks To Enter mRNA Technology, Says Chairman: Reuters
30 Novartis says it overpaid Roche's Genentech nearly $210M in a licensing deal—and it wants its money back
31 NOVARTIS AG : Gets a Buy rating from Morgan Stanley
32 Novartis weighs entry into mRNA technology, chairman tells paper
33 Novartis secures listing on Scottish NHS for self-injected MS therapy, move tracks NICE endorsement
34 Why Novartis (NVS) Might Surprise This Earnings Season
35 Novartis in East Hanover plans to sell off 62 of 202 acres (copy)
36 A Chinese I/O biotech looking to turn around an old Novartis program gets a new fundraise after launching PhIII study
37 Novartis CEO on Second-Quarter, Growth, Covid Vaccine Trial
38 Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
39 Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance
40 Lung Transplant Market Is Booming Worldwide | Sanofi, Pfizer, Novartis
41 New to the party, Novartis seeks to plunge into mRNA
42 Novartis takes Leqvio in-house to get submission back on track
43 Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey
44 Novartis AG
45 Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends
46 Novartis' ianalumab's chances to move to next development stage
47 Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran's US Success
48 Hedge Funds Never Been Less Bullish On Novartis AG (NVS)
49 Novartis Sales, Profit Seen Rising in 2Q -- Earnings Preview
50 Novartis fights Roche in $210 mln U.S. dispute over licensing fees
51 Novartis Shorted Rival Up To $47M In IP Royalties, Jury Told
52 AGC Biologics expands further in Colorado with purchase of Novartis Gene Therapies plant
53 Global Dry Eye Medication Market Report 2021 Featuring Novartis, Allergan, Otsuka, Santen Pharmaceutical, and Auven Therapeutics
54 Novartis Korea to continue discussing reimbursement plan for SMA drug Zolgensma
55 How a Novartis CTO uses engineering skills to help women in STEM
56 Dry Eye Disease Clinical Landscape Report 2021: Novartis Leads Industry Sponsors with the Highest Overall Number
57 Novartis : ESG Update
58 Ruxolitinib Improves Outcomes for Certain Patients With GvHD
59 Molecular Partners
60 Covid-19 roundup: Study shows J&J's shot is much less effective against Delta variant; Novartis open to manufacturing other coronavirus vaccines — report
61 Novartis in East Hanover plans to sell off 62 of 202 acres
62 Is Novartis (VTX:NOVN) Using Too Much Debt?
63 The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
64 Do Analysts Agree Thursday on Novartis AG (NVS) Stock's Target Price?
65 Novartis (NYSE:NVS) Rating Lowered to Sell at Zacks Investment Research
66 Novartis moves court against Roche seeking Rs 1565 crore overpaid amount in patent licensing pact
67 Drug Transport Technology Market May Set New Growth Story | Novartis, Roche, Pfizer, Antares Pharma – The Manomet Current
68 Nanopharmaceuticals Market- a Worth Observing Growth: Merck, Pfizer, Novartis, Abbott – Domestic Violence
69 Ofloxacin Eye Drops Market Global Industry Analysis and Forecast Till 2027| Novartis AG, Allergan, Inc., Meda Pharmaceuticals Inc, Bausch & Lomb Inc – The Manomet Current
70 Novartis AG
71 Biopharmaceutical Market Competitive Research And Precise Outlook 2021 to 2028 | Novartis AG, Biogen Idec – The Manomet Current
72 Global Carcinoid Tumor Market Significant Demand Foreseen by 2027 Market | Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Dauntless Pharmaceuticals, Hutchison MediPharma Limited, Aegis Therapeutics, Ispen, & others – The Manomet Curr
73 An opportunity of high quality: Novartis AG (NVS)
74 Novartis AG (NVS), AcelRx Pharmaceuticals Inc. (ACRX): Might Equate To Grow Up
75 Global Antibiotics Market 2021 Business Standards and Competition Landscape 2027 |Novartis AG, Bayer AG, Janssen Pharmaceuticals, Astellas Pharma, Inc., Pfizer, Inc. – The Manomet Current
76 Global Triazolam Market 2021 Worldwide Major Growth by Key Players – Pfizer, Novartis, Sanofi, Nhwa-group, Merck – Domestic Violence
77 Moyamoya disease Market Likely to Boost Future Growth by 2026 | Cephalon, Novartis,Cordis, Sanofi – The Manomet Current
78 Hypertrophic Cardiomyopathy (HCM) Market Research Report0: Major Players Include Mavacamten (Bristol Myers Squibb), CK-274 (Cytokinetics), and LCZ696 (Novartis)
79 Global markets live: Netflix, Novartis, Tesla, Autodesk, AMC...
80 Macular Edema Therapeutics Market to Witness Explosive Rise by 2027 | Allergan, Novartis, Roche – Murphy's Hockey Law
81 Gene Transplant Market Innovative Strategy by 2028 | Gilead (Kite Pharma), Amgen (BioVex), Novartis, – Domestic Violence
82 Incredible Growth of Opthalmic Therapeutic Market by 2027 | Pfizer, Novartis, GlaxoSmithKline – Murphy's Hockey Law
83 Dry Eye Drugs Market Size And Trend by 2027| Allergan, Novartis AG, Bausch Health
84 Huge Demand of Arthritis Drug Market by 2027 | Novartis, Eli Lilly, Celltrion – Murphy's Hockey Law
85 Facial Aesthetics Market Will Hit Big Revenues In Future ||Novartis AG; Johnson & Johnson Services,
86 Huge Demand of Periodic Fever Syndrome Market by 2027 | Novartis, Simvastatin, Merck – Murphy's Hockey Law
87 Artios Pharma Ltd raises US-$153m Series C financing
88 Herpes Simplex Virus Treatment Market to Witness Explosive Rise by 2027 | Novartis, Pfizer, Abbott Laboratories – Murphy's Hockey Law
89 Precision Medicine Market Trend Analysis 2021-2025: Novartis International AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd. – SoccerNurds
90 Sarcoidosis Drug Market 2021-2031 Report SWOT Analysis, by Key Players- Novartis AG, PharmaIN, Corp, Adaptimmune Therapeutics plc – The Manomet Current
91 Pharmacological Antidotes Market Analysis 2021, Growth, Opportunity Assessments| Roche, Pfizer, Novartis, Mylan – Murphy's Hockey Law
92 Opthalmic Therapeutic Market 2021 also Industry is Booming Worldwide with Key Players | Pfizer, Novartis, GlaxoSmithKline, etc. – Domestic Violence
93 When Novartis (NVS) Moves Investors should Listen
94 Indacaterol Market Size, CAGR | Key Players – Sunovion Pharmaceuticals, Novartis, .,,, – The Manomet Current
95 Epilepsy Therapeutics Market to Witness Robust Expansion by 2027 | Bausch Health Companies Inc, Novartis AG, Sunovion Pharmaceuticals Inc., Eisai Co., Amneal Pharmaceuticals LLC. – The Manomet Current
96 Pazopanib Market Size, CAGR | Key Players – Novartis, GlaxoSmithKline, .,,, – The Manomet Current
97 Futuristics Overview of Urological Cancer Drugs Market: Industry Insights and Forecast 2021-2026 by Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Abbott Laboratories, and more | Affluence – Domestic Violence
98 Qualitative Analysis of Vinorelbine Tartrate Market 2021-2026 Strategical Assessment of Novartis, Pierre Fabre, Hospira, Hikma, Fresenius Kabi, Mylan, and more | Affluence – Murphy's Hockey Law
99 Ceritinib Market Size, CAGR | Key Players – Novartis, Natco, Lucius Pharmaceuticals, .,, – The Manomet Current
100 Antifungal Therapeutics Market Size, CAGR | Key Players – Pfizer, Merck, GSK, Novartis, Roche, Sanofi – The Manomet Current